Welcure Drugs and Pharmaceuticals Limited (BOM:524661)
India · Delayed Price · Currency is INR 0.1800
-0.0100 (-5.26%)
At close: Nov 6, 2026
BOM:524661 Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 222 | 297 | 1,023 | 51 | 54 | 132 | |
Market Cap Growth | -64.71% | -71.00% | 1913.04% | -6.47% | -58.85% | 419.68% |
Enterprise Value | 217 | 1,527 | 1,020 | 50 | 40 | 132 |
Last Close Price | 0.18 | 0.24 | 0.83 | 0.34 | 0.37 | 0.89 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | - | - | 47.13 | - | 53.41 | 559.87 |
PS Ratio | 0.06 | 0.08 | 4.17 | - | - | 125.73 |
PB Ratio | 0.23 | 0.31 | 1.00 | 3.79 | 3.59 | 141.95 |
P/TBV Ratio | 0.23 | 0.31 | 1.00 | 3.79 | 3.59 | 141.95 |
P/FCF Ratio | 12.82 | 17.09 | - | - | 50.81 | 711.56 |
P/OCF Ratio | 12.82 | 17.09 | - | - | 50.81 | 711.56 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 0.06 | 0.42 | 4.16 | - | - | 125.64 |
EV/EBITDA Ratio | - | - | 36.61 | 41.29 | 89.54 | - |
EV/EBIT Ratio | - | - | 36.71 | 58.48 | 96.55 | 559.47 |
EV/FCF Ratio | 12.49 | 88.02 | - | - | 37.12 | 711.06 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | - | - | 1.20 | - | - | - |
Debt / EBITDA Ratio | - | - | 44.19 | - | - | - |
Net Debt / Equity Ratio | -0.01 | -0.01 | 1.20 | -0.02 | 0.00 | -0.71 |
Net Debt / EBITDA Ratio | 0.11 | 0.11 | 44.15 | -0.18 | -0.03 | - |
Net Debt / FCF Ratio | -0.33 | -0.33 | -0.55 | 0.17 | -0.01 | -3.56 |
Asset Turnover | 0.94 | 0.94 | 0.18 | - | - | 1.24 |
Inventory Turnover | 2.25 | 2.25 | - | - | - | - |
Quick Ratio | 0.52 | 0.52 | 0.46 | 0.71 | 0.09 | 17.30 |
Current Ratio | 0.87 | 0.87 | 4.41 | 1.04 | 0.43 | 17.30 |
Return on Equity (ROE) | -5.50% | -5.50% | 4.18% | -12.24% | 12.65% | 29.03% |
Return on Assets (ROA) | -0.88% | -0.88% | 1.29% | 3.72% | 3.16% | 17.36% |
Return on Invested Capital (ROIC) | -3.10% | -3.41% | 1.91% | 6.09% | 5.33% | 96.32% |
Return on Capital Employed (ROCE) | -5.70% | -5.70% | 1.20% | 6.40% | 2.70% | 25.40% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | -22.22% | -18.51% | 2.12% | -3.44% | 1.87% | 0.18% |
FCF Yield | 7.80% | 5.85% | -217.11% | -2.51% | 1.97% | 0.14% |
Buyback Yield / Dilution | -59.83% | -59.83% | -477.75% | -0.54% | -10.90% | - |